Bristol-Myers Squibb News

Bristol-Myers Squibb Company announced interim results from the expanded Phase 1 dose-ranging study 003 of its investigational anti-PD-1 immunotherapy , which showed clinical activity in patients with previously-treated non small-cell lung cancer , metastatic melanoma and renal cell carcinoma .

An experimental Bristol-Myers Squibb drug helped shrink tumors in patients with advanced melanoma, kidney and lung cancers in a preliminary trial, raising hopes for yet another drug that can wake up the immune system and train it to attack cancer cells.

A Cancer Research UK initiative to improve cancer gene testing has prompted two pharmaceutical companies to plan pioneering international trials into targeted cancer treatments in the UK.

Overview -- Standard & Poor's Ratings Services has revised its criteria regarding the linkage of issuers' long-term and short-term ratings as they relate to liquidity.

Bristol-Myers Squibb is making progress developing a new drug to assist the body's immune system in its ability to find and attack cancer cells.

U.S. Republican presidential candidate and former Governor of Massachusetts Mitt Romney addresses supporters during his Wisconsin and Maryland primary night rally in Milwaukee, Wisconsin, April 3, 2012.

In addition to Bristol-Myers Squibb, the II-ON is currently comprised of ten leading cancer-research institutions, including: "The shared commitment of all those participating in this collaboration is to evolve our understanding of immuno-oncology towards our ultimate goal of improving patient outcomes." .Clinica Universidad Navarra, Pamplona, ... (more)

Bristol-Myers Squibb has formed the International Immuno-Oncology Network , a global collaboration between industry and academia intended to further the scientific understanding of immuno-oncology. Immuno-oncology focuses on the potential of harnessing the body's immune system to fight cancer.

America is sticking people in prison like it's a frivolous contest when instead the numbers add up to a great cruelty that achieves minimal good.

America is sticking people in prison like it's a frivolous contest when instead the numbers add up to a great cruelty that achieves minimal good.

It is a day for everyone, whether you're a cancer survivor, a family member, friend, or medical professional.

Lamberto Andreotti , chief executive officer, will answer questions about the company at 9 a.m. EST.

There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve.

A scientist for the French firm Sanofi-Aventis, which made and marketed the blood-thinner with Bristol-Myers Squibb.

Shares of Bristol Myers Squibb opened at 32.75 on Friday. Bristol Myers Squibb has a 52 week low of $25.69 and a 52 week high of $35.44. The company has a market cap of $55.318 billion and a P/E ratio of 14.69. Bristol Myers Squibb last announced its earnings results on Thursday, April 26th.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia May 16, 2012 -- Announcing two separate strategic China initiatives yesterday, Bristol-Myers Squibb increased its commitment to building its presence in China and its bid for ... (more)

Editor's Note: The following advisory was issued today by the Lawrence Township Health Department.

Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.'s Plavix after the drug loses U.S. patent protection Thursday.

Hypothesis We hypothesized that costs for NVAF patients rise acutely following a major bleed and stay elevated through extended follow-up compared with costs for NVAF patients without a major bleed.

Methods Patients who initiated warfarin therapy between Jan 2005 and Jun 2009 and had a healthcare claim related to AF within 30 days prior to the first warfarin claim, but no evidence of valvular disease, were included.